Yu Jonathan Yen-Wen 4

What Happened
Yu Jonathan Yen-Wen, Chief Operating Officer of Disc Medicine, received equity awards reported on a Form 4 dated Feb 11, 2026 for transactions on Feb 10, 2026. The filing shows: 17,000 restricted stock units (RSUs) granted and 25,500 derivative awards (option-type award) granted, both reported at $0.00 in the filing. Combined, these awards represent the potential issuance of 42,500 shares if and when they vest/are settled.

Key Details

• Transaction date: 2026-02-10; Form 4 filed: 2026-02-11 (timely filing).
• Reported acquisition amounts/prices: 17,000 RSUs @ $0.00; 25,500 derivative award units @ $0.00.
• Shares owned after transaction: not specified in this filing.
• Footnotes:
  • F1 (RSUs): Each RSU converts to one share on vesting; they vest annually in four equal 25% installments beginning Feb 15, 2027, subject to continued service.
  • F2 (derivative award): Underlying shares vest in 48 equal monthly installments beginning March 10, 2026, subject to continued service.
• Transaction code: A = Award/Grant. No sales, purchases, or cashless exercise reported here.

Context
These grants are compensation awards, not open-market purchases or sales. RSUs convert into actual shares only as they vest; the derivative award similarly vests over time. Until vesting (and any subsequent exercise or sale), these awards do not represent immediately tradable shares and should be viewed as part of executive compensation rather than a direct trading signal.